27/10/08
Launch of a ph.III clinical trial in adults for Oralair Grasses in the US
Operating income expected to remain stable in 2009
15/10/08
Quarterly information: Continuing growth dynamics
Sales at end September 2008: +17%
2008 sales guidance revised upwards:...
07/10/08
Partnership with Catalent and The Medical House
Partnership for commercialization of adrenaline autoinjector in Europe
Last update: 07/10/2008
Stallergenes is a European biopharmaceutical laboratory specialising in the treatment by desensitisation of allergy-related respiratory conditions.
The Group's activities focus on research into allergy, and the development, production and distribution of allergen extracts for the curative treatment of allergic rhinitis and asthma.
